Table 2.
Among survivors eligible for pediatric follow-up, characteristics of survivors who returned to survivor clinic compared to those with no follow-up visit
| Characteristic | Follow-up Visit n (%) | No Follow-up Visit n (%) | p-value | aOR (95% CI) | p-value |
|---|---|---|---|---|---|
| Overall | 496 (88.6%) | 64 (11.4%) | |||
| Survivor Gender | |||||
| Male | 270 (90.0%) | 30 (10.0%) | 0.25 | ||
| Female | 226 (86.9%) | 34 (13.1%) | |||
| Survivor Race/Ethnicity | |||||
| White, non-Hispanic | 337 (88.0%) | 46 (12.0%) | 0.52 | 0.8 (0.4, 1.4) | 0.39 |
| non-White | 159 (89.8%) | 18 (10.2%) | Ref | ||
| Age at Diagnosis | |||||
| <5 yrs | 311 (87.9%) | 43 (12.1%) | 0.33 | ||
| 5–9.9 yrs | 109 (91.6%) | 10 (8.4%) | |||
| 10–14.9 yrs | 63 (90.0%) | 7 (10.0%) | |||
| 15–20.9 yrs | 13 (76.5%) | 4 (23.5%) | |||
| Treatment | |||||
| Chemotherapy &/or Surgery Only | 298 (86.6%) | 46 (13.4%) | 0.11 | ||
| Radiation (no BMT) | 120 (90.2%) | 13 (9.8%) | |||
| BMT | 78 (94.0%) | 5 (6.0%) | |||
| History of Relapse/SMN | |||||
| None | 421 (87.0%) | 63 (13.0%) | <0.001 | Ref | 0.01 |
| History of Relapse/SMN | 75 (98.7%) | 1 (1.3%) | 11.9 (1.6, 87.9) | ||
| Time Since Completion of Therapy | |||||
| <5 yrs | 217 (91.2%) | 21 (8.8%) | 0.06 | ||
| 5–10 yrs | 199 (88.8%) | 25 (11.2%) | |||
| 10+yrs | 80 (81.6%) | 18 (18.4%) | |||
| Clinic Visit Type | |||||
| First Survivor Visit | 152 (87.9%) | 21 (12.1%) | 0.73 | ||
| Follow-up Survivor Visit | 344 (88.9%) | 43 (11.1%) | |||
| Age at Survivor Visit | |||||
| 2–9.9 yrs | 132 (93.0%) | 10 (7.0%) | 0.10 | Ref | |
| 10–14.9 yrs | 192 (87.3%) | 28 (12.7%) | 0.5 (0.2, 1.1) | 0.07 | |
| 15–17.9 yrs | 107 (89.9%) | 12 (10.1%) | 0.7 (0.3, 1.6) | 0.39 | |
| 18–21.9 yrs | 65 (82.3%) | 14 (17.7%) | 0.3 (0.1, 0.8) | 0.01 | |
| Insurance | |||||
| Private | 308 (88.0%) | 42 (12.0%) | 0.26 | ||
| Public | 184 (90.2%) | 20 (9.8%) | |||
| None | 4 (66.7%) | 2 (33.3%) | |||
| SurvivorLink Use | |||||
| Not Registered | 368 (86.8%) | 56 (13.2%) | 0.02 | Ref | |
| Registrant | 128 (94.1%) | 8 (5.9%) | 2.6 (1.2, 5.8) | 0.02 | |
BMT = Bone Marrow Transplant; SMN Second Malignancy